Taming the FDA

Evans, M. Stanton
February 1978
National Review;2/17/1978, Vol. 30 Issue 7, p219
Comments on proposed bills to remove from the U.S. Food and Drug Administration (FDA) the power to determine the efficacy of ethical drugs. Estimated time lag in getting approval of new drugs that come on the market; Increase in the average cost of bringing a new drug to the American market.


Related Articles

  • New FDA Approvals.  // Drug Utilization Review;Feb2002, Vol. 18 Issue 2, p8 

    Presents updates related to the United States Food and Drug Administration drug approvals as of February 2002, citing the approval for Fondaparinux sodium.

  • Final DSHEA rules may be delayed.  // Drug Store News;8/5/96, Vol. 18 Issue 12, p32 

    Reports that the Dietary Supplement Health and Education Act of 1994 freed pharmaceutical manufacturers to communicate product benefits to consumers and put the burden on the Food and Drug Administration to prove products unsafe.

  • Accelerated approvals examined. Dorey, Emma // Nature Biotechnology;Mar2011, Vol. 29 Issue 3, p176 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to review several drugs approved under the much-criticized accelerated approval program in March 2011, which include Amgen's Vectibix, Genzyme's Clolar and GlaxoSmithKline's Bexxar.

  • Opinion: A proposal for FDA reform. Miller, Henry I. // Nature Reviews Drug Discovery;Aug2002, Vol. 1 Issue 8, p642 

    Since the current system for the regulation of drugs in the United States was established in 1962, the FDA has steadily increased the scope of its responsibilities and activities, and, concomitantly, the regulatory burden on drug developers. The costs and time that are required for drug...

  • Anesta amends NDA after `not approvable.' Dickinson, James G. // Medical Marketing & Media;Jun98, Vol. 33 Issue 6, p30 

    Focuses on the amendments made to Actiq (oral transmucosal fentanyl citrate), produced by the Anesta Corporation, following a request made by the United States Food and Drug Administration (FDA). Approval given to the drug by the FDA.

  • FDA revamps drug manufacturing rules. Dickinson, James G. // Medical Marketing & Media;Oct2002, Vol. 37 Issue 10, p26 

    Reports on the revamp of the drug manufacturing rules by the U.S. Food and Drug Administration. Importance of scientific advances in pharmaceutical manufacturing; Balance between product quality concerns and technological innovation; Focus of the agency on the public health risks.

  • Congress Renews User Fees, Boosts Bioterror Provisions. Wechsler, Jill // Pharmaceutical Executive;Jul2002, Vol. 22 Issue 7, p30 

    Examines the provisions of the Prescription Drug User Fee Act (PDUFA) and the implications for the U.S. Food Drug Administration. Increase in the funding given to the agency; Initiatives to streamline the drug development and approval process; Rise in user fees under PDUFA.

  • BUYING TIME. Parker, Thomas J.; Manning, Amy S. // Pharmaceutical Executive;Jul2002, Vol. 22 Issue 7, p68 

    Examines the provisions of the Best Pharmaceuticals for Children Act (BPCA) of the U.S. and how they affect the pharmaceutical industry. Purpose of the BPCA; Role of the BPCA in extending the pediatric exclusivity provision of the Food and Drug Administration Modernization Act of 1997;...

  • Private agencies could speed drug approval. Kleiner, Kurt // New Scientist;3/2/96, Vol. 149 Issue 2019, p10 

    Reports on the US Senate's plan to introduce a bill that would allow private companies to approve new drugs when the US Food and Drug Administration does not act quickly enough. Advantages of the bill.

  • Clamor over approval times fans FDA reform debate. Conlan, Michael F. // Drug Topics;1/22/96, Vol. 140 Issue 2, p72 

    Reports on the legislative divide over the drug lag in the United States in the midst of the expected reform of the Food and Drug Administration (FDA). Reform bill drafted by Representative Thomas Bliley; Report on drug approval times released by Representative David A. Kessler; Issue regarding...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics